Clinical trial
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04097821 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT04097821 |
|---|---|
| Title | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
| Official title | A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
| Acronym | ADORE |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis |
| Intervention type | Drug |
| Interventions | Ruxolitinib, Siremadlin, Crizanlizumab, Sabatolimab, Rineterkib, NIS793 |
| Enrollment | 45 |
| Start date | Sep 26, 2019 |
| Primary completion | May 3, 2023 |
| Completion | Aug 28, 2024 |
| First posted | Sep 20, 2019 |
| Last update posted | Aug 7, 2025 |
| Countries | Australia, Canada, Denmark, Germany, Hungary, Italy, Netherlands, Russia, Spain, Sweden, Switzerland, Turkey (Türkiye) and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: